Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
The Central Social Insurance Medical Council (Chuikyo) on August 7 approved 12 medicines for reimbursement listing later this month, with the largest peak sales projected for Novartis Pharma’s Fabhalta (iptacopan), a treatment for paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is expected…
To read the full story
Related Article
- Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
- Pfizer’s Antibiotic Zavicefta Now Available in Japan
November 13, 2024
- Haihe’s MET Inhibitor Haiyitan Set for Launch on Oct. 11
September 25, 2024
- UCB’s Anti-Epileptic Drug Briviact Now Available in Japan
September 2, 2024
- Takeda Rolls Out CMV Drug Livtencity in Japan
August 29, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- Lilly’s BTK Inhibitor Jaypirca Hits Japan Market for MCL
August 22, 2024
- Fabhalta, Omjjara, Avigan Now Available in Japan
August 19, 2024
REGULATORY
- LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
- Senior LDP Lawmakers Call for “Net Plus” in FY2026 Fee, Drug Price Revisions
December 10, 2025
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…